Walaliyadde: Non-invasive prenatal testing was the first genetic application and is saturated
Malinka Walaliyadde · a16z Podcast | On the Genomics of Disease, From Science to Business · Jan 2, 2019 · at 27:36
Malinka Walaliyadde of Andreessen Horowitz evaluates the maturity and market opportunity across different commercial verticals in human genomics.
0:00 / 0:07exact quote · 7.3s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Non-invasive prenatal testing and infertility is one major area. In fact, that was the first. It was the first to make it big in genetics, and it's gotten a little saturated.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Malinka Walaliyadde
Walaliade: AI models outperform human physicians in top 2017 medical journals
“Two years ago, there weren't that many examples of prominent journals publishing AI and healthcare pieces where it was, you know, shown to work in healthcare context, and now it feels like every month there's a new nature paper or something coming out where, y…”
Walaliate: Genomics has few true healthcare applications 20 years after HGP
“We certainly haven't lived up to that, and in fact, it's been a little difficult to see exactly where genomics has had a true application today.”
Walaliyadde: The magical continuous diagnostic machine of the future is your bathroom
“I actually think the magical diagnostic machine of the future is your bathroom.”
Walaliyadde: Assurex generated $60M in revenue despite only 20% test reimbursement
“There's a company called Assurex in mental health. They were making sixty million dollars in revenue last year, but they were only getting 20% of their tests reimbursed.”
Walaliade: Hospitals are increasingly taking financial risk for patient care
“Hospitals are increasingly taking financial risk on their patients. They are financially on the hook for excessive care.”
Walaliade: Health plans demand cost-saving proof over product engagement
“Health insurance plans care a lot more about saving money than offering an engaging product and so for an early-stage startup, it's a lot harder for them to do the saving money piece, because that takes a long study to prove, and they do it eventually, but it'…”